Core Viewpoint - The company plans to launch an H-share listing to enhance its capital strength and overseas financing capabilities, aiming to improve overall competitiveness and accelerate international business strategy [1] Financial Performance - For the first three quarters of 2025, the company reported revenue of 2.45 billion (+25.5%) and a net profit attributable to shareholders of 244 million (+2.13%), with a non-recurring net profit of 214 million (-5.4%) [1] - In Q3 2025, revenue reached 690 million (+14.3%), net profit attributable to shareholders was 69 million (+11.6%), and non-recurring net profit was 48 million (-20%) [1] - The company corrected its H1 financial data, adjusting revenue down by 4.55 million, increasing management expenses by 10.27 million, and reducing net profit attributable to shareholders by 11.33 million [1] Profitability Metrics - Q3 2025 gross margin was 75.72% (+1.2 percentage points), with a sales expense ratio of 60.52% (+1.6 percentage points), management expense ratio of 5.89% (+1.8 percentage points), and R&D expense ratio of 3.32% (+0.2 percentage points) [1] - The net profit margin attributable to shareholders in Q3 2025 was 10.13% (-0.2 percentage points), and the non-recurring net profit margin was 7% (-3 percentage points) [1] Investment Outlook - The company is currently in a growth phase with increased expenses impacting short-term profitability, and it is essential to track the effectiveness of expanding its customer base [2] - Future focus should be on new customer conversion and the pace of profit recovery [2] - Projected net profits attributable to shareholders for 2025 and 2026 are 370 million and 460 million, respectively, corresponding to PE ratios of 36x and 29x [3]

Core Insights - The company, Guangdong Marubi Biotechnology Co., Ltd., reported a robust growth in profitability for the third quarter of 2025, with significant acceleration in growth momentum [1] Financial Performance - From January to September 2025, the company achieved a net profit attributable to shareholders of 244 million yuan, maintaining steady growth despite a high base from the previous year [1] - The third quarter net profit attributable to shareholders reached 69.4816 million yuan, with a year-on-year growth rate of 11.59%, indicating a notable improvement compared to the cumulative growth rate for the first three quarters [1] - Basic earnings per share for the third quarter were 0.18 yuan, reflecting a year-on-year increase of 12.5%, which outpaced the net profit growth rate, showcasing the company's ability to enhance shareholder value [1] Growth Momentum - The company not only maintained stable profit levels in the first three quarters of 2025 but also demonstrated strong growth momentum in both profit and earnings per share, with both metrics exceeding 10% year-on-year growth in the third quarter [1]